Key result
Heart-specific overexpression of IRF7 significantly attenuated pressure overload-induced cardiac hypertrophy, fibrosis, and dysfunction by inhibiting nuclear factor-κB signaling.
Why the study?
Does IRF7 overexpression prevent pathological cardiac hypertrophy in mouse models?
Does IRF7 overexpression prevent pathological cardiac hypertrophy in mouse models?
IRF7 acts as a novel negative regulator of pathological cardiac hypertrophy by inhibiting NF-κB signaling, identifying it as a potential therapeutic target.
No takes yet. Share an insight, caveat, or question.
Does not support clinical use; leaves open IRF7 as a therapeutic target pending human studies.
Jiang et al. (2014) studied Pathological cardiac hypertrophy. IRF7 overexpression or deficiency vs. Wild-type littermates was evaluated on Cardiac hypertrophy, fibrosis, and dysfunction. Heart-specific overexpression of IRF7 significantly attenuated pressure overload-induced cardiac hypertrophy, fibrosis, and dysfunction by inhibiting nuclear factor-κB signaling.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: